The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes

Ernesto S. Nakayasu, Wei Jun Qian, Carmella Evans-Molina, Raghu Mirmira, Decio L. Eizirik, Thomas O. Metz

Research output: Contribution to journalReview article

Abstract

Introduction: Type 1 diabetes (T1D) is characterized by autoimmune-induced dysfunction and destruction of the pancreatic beta cells. Unfortunately, this process is poorly understood, and the current best treatment for type 1 diabetes is the administration of exogenous insulin. To better understand these mechanisms and to develop new therapies, there is an urgent need for biomarkers that can reliably predict disease stage. Areas covered: Mass spectrometry (MS)-based proteomics and complementary techniques play an important role in understanding the autoimmune response, inflammation and beta-cell death. MS is also a leading technology for the identification of biomarkers. This, and the technical difficulties and new technologies that provide opportunities to characterize small amounts of sample in great depth and to analyze large sample cohorts will be discussed in this review. Expert opinion: Understanding disease mechanisms and the discovery of disease-associated biomarkers are highly interconnected goals. Ideal biomarkers would be molecules specific to the different stages of the disease process that are released from beta cells to the bloodstream. However, such molecules are likely to be present in trace amounts in the blood due to the small number of pancreatic beta cells in the human body and the heterogeneity of the target organ and disease process.

Original languageEnglish (US)
Pages (from-to)569-582
Number of pages14
JournalExpert Review of Proteomics
Volume16
Issue number7
DOIs
StatePublished - Jul 3 2019

Fingerprint

Medical problems
Type 1 Diabetes Mellitus
Proteomics
Biomarkers
Cell Death
Insulin-Secreting Cells
Mass spectrometry
Mass Spectrometry
Technology
Molecules
Expert Testimony
Cell death
Autoimmunity
Human Body
Blood
Insulin
Inflammation
Therapeutics

Keywords

  • beta cell dysfunction and death
  • neoantigens
  • type 1 diabetes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes. / Nakayasu, Ernesto S.; Qian, Wei Jun; Evans-Molina, Carmella; Mirmira, Raghu; Eizirik, Decio L.; Metz, Thomas O.

In: Expert Review of Proteomics, Vol. 16, No. 7, 03.07.2019, p. 569-582.

Research output: Contribution to journalReview article

Nakayasu, Ernesto S. ; Qian, Wei Jun ; Evans-Molina, Carmella ; Mirmira, Raghu ; Eizirik, Decio L. ; Metz, Thomas O. / The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes. In: Expert Review of Proteomics. 2019 ; Vol. 16, No. 7. pp. 569-582.
@article{92389f55a2a04001b800ae58e61da1b2,
title = "The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes",
abstract = "Introduction: Type 1 diabetes (T1D) is characterized by autoimmune-induced dysfunction and destruction of the pancreatic beta cells. Unfortunately, this process is poorly understood, and the current best treatment for type 1 diabetes is the administration of exogenous insulin. To better understand these mechanisms and to develop new therapies, there is an urgent need for biomarkers that can reliably predict disease stage. Areas covered: Mass spectrometry (MS)-based proteomics and complementary techniques play an important role in understanding the autoimmune response, inflammation and beta-cell death. MS is also a leading technology for the identification of biomarkers. This, and the technical difficulties and new technologies that provide opportunities to characterize small amounts of sample in great depth and to analyze large sample cohorts will be discussed in this review. Expert opinion: Understanding disease mechanisms and the discovery of disease-associated biomarkers are highly interconnected goals. Ideal biomarkers would be molecules specific to the different stages of the disease process that are released from beta cells to the bloodstream. However, such molecules are likely to be present in trace amounts in the blood due to the small number of pancreatic beta cells in the human body and the heterogeneity of the target organ and disease process.",
keywords = "beta cell dysfunction and death, neoantigens, type 1 diabetes",
author = "Nakayasu, {Ernesto S.} and Qian, {Wei Jun} and Carmella Evans-Molina and Raghu Mirmira and Eizirik, {Decio L.} and Metz, {Thomas O.}",
year = "2019",
month = "7",
day = "3",
doi = "10.1080/14789450.2019.1634548",
language = "English (US)",
volume = "16",
pages = "569--582",
journal = "Expert Review of Proteomics",
issn = "1478-9450",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes

AU - Nakayasu, Ernesto S.

AU - Qian, Wei Jun

AU - Evans-Molina, Carmella

AU - Mirmira, Raghu

AU - Eizirik, Decio L.

AU - Metz, Thomas O.

PY - 2019/7/3

Y1 - 2019/7/3

N2 - Introduction: Type 1 diabetes (T1D) is characterized by autoimmune-induced dysfunction and destruction of the pancreatic beta cells. Unfortunately, this process is poorly understood, and the current best treatment for type 1 diabetes is the administration of exogenous insulin. To better understand these mechanisms and to develop new therapies, there is an urgent need for biomarkers that can reliably predict disease stage. Areas covered: Mass spectrometry (MS)-based proteomics and complementary techniques play an important role in understanding the autoimmune response, inflammation and beta-cell death. MS is also a leading technology for the identification of biomarkers. This, and the technical difficulties and new technologies that provide opportunities to characterize small amounts of sample in great depth and to analyze large sample cohorts will be discussed in this review. Expert opinion: Understanding disease mechanisms and the discovery of disease-associated biomarkers are highly interconnected goals. Ideal biomarkers would be molecules specific to the different stages of the disease process that are released from beta cells to the bloodstream. However, such molecules are likely to be present in trace amounts in the blood due to the small number of pancreatic beta cells in the human body and the heterogeneity of the target organ and disease process.

AB - Introduction: Type 1 diabetes (T1D) is characterized by autoimmune-induced dysfunction and destruction of the pancreatic beta cells. Unfortunately, this process is poorly understood, and the current best treatment for type 1 diabetes is the administration of exogenous insulin. To better understand these mechanisms and to develop new therapies, there is an urgent need for biomarkers that can reliably predict disease stage. Areas covered: Mass spectrometry (MS)-based proteomics and complementary techniques play an important role in understanding the autoimmune response, inflammation and beta-cell death. MS is also a leading technology for the identification of biomarkers. This, and the technical difficulties and new technologies that provide opportunities to characterize small amounts of sample in great depth and to analyze large sample cohorts will be discussed in this review. Expert opinion: Understanding disease mechanisms and the discovery of disease-associated biomarkers are highly interconnected goals. Ideal biomarkers would be molecules specific to the different stages of the disease process that are released from beta cells to the bloodstream. However, such molecules are likely to be present in trace amounts in the blood due to the small number of pancreatic beta cells in the human body and the heterogeneity of the target organ and disease process.

KW - beta cell dysfunction and death

KW - neoantigens

KW - type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85068796464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068796464&partnerID=8YFLogxK

U2 - 10.1080/14789450.2019.1634548

DO - 10.1080/14789450.2019.1634548

M3 - Review article

VL - 16

SP - 569

EP - 582

JO - Expert Review of Proteomics

JF - Expert Review of Proteomics

SN - 1478-9450

IS - 7

ER -